Sébastien Jacquemont


Canada Research Chair in Genetics of Neuropsychiatric Disorders

Tier 2 - 2014-10-01
Renewed: 2019-10-01
Université de Montréal
Canadian Institutes of Health Research

514-345-4931, ext./poste 3698
sebastien.jacquemont@umontreal.ca

Coming to Canada From


University of Lausanne, Switzerland

Research involves


Understanding the effects of genetic variants on brain development and neuropsychiatric disorders.

Research relevance


This research will lead to treatments targeting specific molecular mechanisms in neuropsychiatric disorders.

It’s in the Genes: Understanding Genetic Variants Involved in Neuropsychiatric Disorders


Scientists use genome-wide analysis methods to identify mutations that cause human disease. Many new genetic variations associated with psychiatric disorders have been identified recently, but exactly how they lead to neuropsychiatric disease remains unknown—and is the subject of research by Dr. Sébastien Jacquemont, Canada Research Chair in Genetics of Neuropsychiatric Disorders.

Jacquemont’s research focuses on families with rare genetic mutations that lead to neurodevelopmental disorders like autism, schizophrenia, speech and language impairment, or learning disabilities. These disorders affect more than 5 percent of the general population, and are a significant public health burden. Jacquemont and his research team are investigating how genetic mutations change cognition, behavior and energy balance in these patients by measuring their effects and studying how they shift according to different family backgrounds and environments.

Jacquemont is interested in general patterns of cognitive and behavioral difficulties rather than in a single specific diagnosis. This is because the criteria that currently define neuropsychiatric diagnoses do not capture the whole spectrum of associated disorders or disabilities.

Establishing cohorts of individuals carrying specific mutations offers a promising way to study common neuropsychiatric diseases. Ultimately, this research could lead to successful treatments targeting specific mechanisms involved in neuropsychiatric disorders.